FDA Inspection
Janssen Pharmaceuticals, IncJanssen Pharmaceuticals, Inc – FDA Inspection, Sep 28, 2020
Record Details
This FDA Inspection record concerns Janssen Pharmaceuticals, Inc, with an inspection on September 28, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Janssen Pharmaceuticals, Inc
- Inspection Date
- September 28, 2020
- Product Type
- Drugs
View Company Profile
ID · 3a8fe62f-7bb7-4a30-a70b-ff5a60a6a59a
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1131617
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
Other FDA inspections of Janssen Pharmaceuticals, Inc
12| Date | Classification | Office | Project area |
|---|---|---|---|
| September 25, 2026 | VAI | New Jersey District Office | Postmarket Surv. and Epidemiology |
| August 14, 2025 | Not classified | New Jersey District Office | |
| September 27, 2024 | NAI | New Jersey District Office | Bioresearch Monitoring: Human Drugs |
| September 14, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 6, 2017 | NAI | Center for Devices and Radiological Health | Compliance: Devices |
Other documents for Janssen Pharmaceuticals, Inc
- FDA Inspection 1338168 - 2026-09-25
- FDA Inspection 1271223 - 2025-08-14
- FDA Inspection 1229931 - 2024-09-27
- FDA Inspection 1131381 - 2020-09-14
- FDA Inspection 1031605 - 2017-10-06
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.